cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2026-4850YMJVOUcardiovascular-4850Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESИнструменты скрининга артериальной гипертензии (обзор литературы)Hypertension screening tools: a literature reviewhttps://orcid.org/0000-0003-1882-5038БулгаковаА. С.BulgakovaA. S.

Ассистент кафедры организации здравоохранения и общественного здоровья

Московский тракт, д. 2, Томск, 634050

Assistant Professor at the Department of Healthcare Organization and Public Health

Moskovsky trakt, 2, Tomsk, 634050

alinss6998@mail.ruhttps://orcid.org/0000-0001-7532-7102БойковВ. А.BoykovV. A.

Д.м.н., доцент, зав. кафедрой организации здравоохранения и общественного здоровья

Московский тракт, д. 2, Томск, 634050

Grand PhD in Medical sciences, Associate Professor, Head of the Department of Healthcare Organization and Public Health

Moskovsky trakt, 2, Tomsk, 634050

boykov85@mail.ruhttps://orcid.org/0000-0003-3680-7415ГофманВ. В.HoffmanV. V.

Первый заместитель министра здравоохранения Кузбасса

пр. Советский, д. 58, Кемерово, 650064

First Deputy Minister of Health of Kuzbass

Sovetsky Avenue, 58, Kemerovo, 650064

VVG.email@yandex.ruhttps://orcid.org/0009-0000-7722-1555ГрузныхС. Н.GruznykhS. N.

Заместитель Губернатора Томской области по социальной политике

пл. Ленина, д. 6, Томск, 634050

Deputy Governor of the Tomsk Region for Social Policy

Lenin Square, 6, Tomsk, 634050

social@tomsk.gov.ruhttps://orcid.org/0000-0002-4449-4810ДеевИ. А.DeevI. A.

Профессор кафедры управления, экономики здравоохранения и медицинского страхования Института непрерывного образования и профессионального развития

ул. Островитянова, д. 1, Москва, 117513

Grand PhD in Medical sciences, professor, Professor of the Department of Management, Healthcare Economics and Medical Insurance at the Institute of Continuous Education and Professional Development

Ostrovityanova str., 1, 117513

ivandeyev@yandex.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Д.м.н., профессор, академик РАН, директор

Петроверигский пер., 10, стр. 3, Москва, 101990

Grand PhD in Medical sciences, professor, Academician of the Russian Academy of Sciences, director

Petroverigsky Lane, 10, bld. 3, Moscow, 101990

gnicpm@gnicpm.ruhttps://orcid.org/0000-0003-0098-1403КобяковаО. С.KobyakovaO. S.

Д.м.н., профессор, чл.-корр. РАН, директор

ул. Добролюбова, д. 11, Москва, 127254

Grand PhD in Medical sciences, professor, Corresponding Member of the Russian Academy of Sciences, director

Dobrolyubova str.,11, Moscow, 127254

kobyakovaos@mednet.ruhttps://orcid.org/0000-0003-2062-1536КонцеваяА. В.KontsevayaA. V.

Л.м.н., профессор, зам. директора по научной и аналитической работе

Петроверигский пер., 10, стр. 3, Москва, 101990

Grand PhD in Medical sciences, professor, Deputy Director for Scientific and Analytical Work

Petroverigsky Lane, 10, bld. 3, Moscow, 101990

koncanna@yandex.ruhttps://orcid.org/0000-0002-1168-7405ПерфильеваД. Ю.PerfilevaD. Y.

К.м.н., ассистент кафедры организации здравоохранения и общественного здоровья

Московский тракт, д. 2, Томск, 634050

Ph.D. of Medical Sciences, Assistant Professor at the Department of Healthcare Organization and Public Health

Moskovsky trakt, 2, Tomsk, 634050

 

daria.perfileva@mail.ruhttps://orcid.org/0000-0002-4255-6846ШибалковИ. П.ShibalkovI. P.

К.э.н., советник директора

ул. Добролюбова, д. 11, Москва, 127254

Ph.D. of Economic Sciences, Advisor to the Director

Dobrolyubova str.,11, Moscow, 127254

shibalkov.ivan@yandex.ruФГБОУ ВО "Сибирский государственный медицинский университет" Минздрава РоссииSiberian State Medical UniversityМинистерство здравоохранения КузбассаMinistry of Health of KuzbassАдминистрация Томской областьAdministration of the Tomsk RegionФГАОУ ВО "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Минздрава РоссииPirogov Russian National Research Medical UniversityФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБУ "Центральный научно-исследовательский институт организации и информатизации здравоохранения" Минздрава РоссииResearch Institute of HealthФГБОУ ВО "Сибирский государственный медицинский университет" Минздрава РоссииSiberian State Medical University (SSMU)20261306202625548504850Copyright © Булгакова А.С., Бойков В.А., Гофман В.В., Грузных С.Н., Деев И.А., Драпкина О.М., Кобякова О.С., Концевая А.В., Перфильева Д.Ю., Шибалков И.П., 20262026Булгакова А.С., Бойков В.А., Гофман В.В., Грузных С.Н., Деев И.А., Драпкина О.М., Кобякова О.С., Концевая А.В., Перфильева Д.Ю., Шибалков И.П.Bulgakova A.S., Boykov V.A., Hoffman V.V., Gruznykh S.N., Deev I.A., Drapkina O.M., Kobyakova O.S., Kontsevaya A.V., Perfileva D.Y., Shibalkov I.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/4850

В Российской Федерации артериальная гипертензия (АГ) по-прежнему остается социально-значимым заболеванием, определяющим высокую нагрузку на систему здравоохранения и весомый социально-экономический ущерб. В настоящее время наиболее распространенным и стандартным методом скрининга АГ является непосредственное измерение уровня артериального давления в условиях медицинской организации. Однако охват населения остаётся неполным — прежде всего из-за низкой профилактической активности определённых возрастных групп, в первую очередь, молодёжи и лиц трудоспособного возраста. Высокая распространенность АГ и ее последствия обусловливают необходимость разработки неинвазивных популяционных инструментов скрининга, нацеленных на ранее выявление факторов риска развития АГ или скрытого течения заболевания среди разных возрастных групп. Наиболее доступным и простым инструментом популяционного скрининга может стать вопросник. В настоящем обзоре проанализирован и обобщен опыт использования вопросников в качестве инструмента скрининга АГ в различных странах мира. По результатам обзора предложена модель популяционного скрининга АГ и факторов риска ее развития вне медицинской организации.

In the Russian Federation, hypertension (HTN) remains a socially significant disease with a high burden on the healthcare system causing significant socioeconomic losses. Currently, the most common and standard method of screening for HTN is direct blood pressure measurement in a healthcare facility. However, population coverage remains incomplete, primarily due to low preventive activity in certain age groups, particularly young people and individuals of working age. The high prevalence of HTN and its consequences necessitate the development of non-invasive population-based screening tools aimed at the early detection of HTN risk factors or the underlying disease among different age groups. A questionnaire may be the most accessible and simple population-based screening tool. This review analyzes and summarizes the experience of using questionnaires as a screening tool for HTN in various countries. Based on the review results, a model for population-based screening for HTN and its risk factors outside of healthcare facilities is proposed.

артериальная гипертензияпопуляционный скринингфакторы рискашкала прогнозированияинструменты скринингавопросникhypertensionpopulation-based screeningrisk factorsprognostic scalescreening toolsquestionnaireReferencesChen S, Sudharsanan N, Huang F, et al. Impact of community based screening for hypertension on blood pressure after two years: regression discontinuity analysis in a national cohort of older adults in China. BMJ. 2019;366:l4064. doi:10.1136/bmj.l4064.Chen S, Sudharsanan N, Huang F, et al. Impact of community based screening for hypertension on blood pressure after two years: regression discontinuity analysis in a national cohort of older adults in China. BMJ. 2019;366:l4064. doi:10.1136/bmj.l4064.Баланова Ю. А., Драпкина О. М., Куценко В. А. и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3785. doi:10.15829/1728-8800-2023-3785. EDN: YRUNUX.Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) doi:10.15829/1728-8800-2023-3785. EDN: YRUNUX.Драпкина О. М., Концевая А. В., Деев И. А. Программный подход к профилактике и контролю артериальной гипертонии как ключевой резерв снижения смертности в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2025;24(12):4698. doi:10.15829/1728-8800-2025-4698. EDN: KRABNJ.Drapkina OM, Kontsevaya AV, Deev IA. Programmatic approach to the prevention and control of hypertension as a key reserve for reducing mortality in the Russian Federation. Cardiovascular Therapy and Prevention. 2025;24(12):4698. (In Russ.) doi:10.15829/1728-8800-2025-4698. EDN: KRABNJ.Rahman M, Zaman MM, Islam JY, et al. Prevalence, treatment patterns, and risk factors of hypertension and pre-hypertension among Bangladeshi adults. J Hum Hypertens. 2018;32(5):334-48. doi:10.1038/s41371-017-0018-x.Rahman M, Zaman MM, Islam JY, et al. Prevalence, treatment patterns, and risk factors of hypertension and pre-hypertension among Bangladeshi adults. J Hum Hypertens. 2018;32(5):334-48. doi:10.1038/s41371-017-0018-x.Mamdouh H, Alnakhi WK, Hussain HY, et al. Prevalence and associated risk factors of hypertension and pre-hypertension among the adult population: findings from the Dubai Household Survey, 2019. BMC Cardiovasc Disord. 2022;22(1):18. doi:10.1186/s12872-022-02457-4.Mamdouh H, Alnakhi WK, Hussain HY, et al. Prevalence and associated risk factors of hypertension and pre-hypertension among the adult population: findings from the Dubai Household Survey, 2019. BMC Cardiovasc Disord. 2022;22(1):18. doi:10.1186/s12872-022-02457-4.Reddy SP, Mbewu AD, Williams DR, et al. Race, geographical location and other risk factors for hypertension: South African National Health and Nutrition Examination Survey 2011/12. SSM. Popul Health. 2021;16:100986. doi:10.1016/j.ssmph.2021.100986.Reddy SP, Mbewu AD, Williams DR, et al. Race, geographical location and other risk factors for hypertension: South African National Health and Nutrition Examination Survey 2011/12. SSM. Popul Health. 2021;16:100986. doi:10.1016/j.ssmph.2021.100986.Dereje N, Earsido A, Temam L, et al. Uncovering the high burden of hypertension and its predictors among adult population in Hosanna town, southern Ethiopia: a community-­based cross-­sectional study. BMJ Open. 2020;10(10):e035823. doi:10.1136/bmjopen-2019-035823.Dereje N, Earsido A, Temam L, et al. Uncovering the high burden of hypertension and its predictors among adult population in Hosanna town, southern Ethiopia: a community-­based cross-­sectional study. BMJ Open. 2020;10(10):e035823. doi:10.1136/bmjopen-2019-035823.Dhungana RR, Pedisic Z, Dhimal M, et al. Hypertension screening, awareness, treatment, and control: a study of their prevalence and associated factors in a nationally representative sample from Nepal. Glob Health Action. 2022;15(1):2000092. doi:10.1080/16549716.2021.2000092.Dhungana RR, Pedisic Z, Dhimal M, et al. Hypertension screening, awareness, treatment, and control: a study of their prevalence and associated factors in a nationally representative sample from Nepal. Glob Health Action. 2022;15(1):2000092. doi:10.1080/16549716.2021.2000092.Amadi CE, Ale OK, Okorafor UC, et al. Unmasking the contem­porary burden of hypertension in Lagos, Nigeria: insights from an opportunistic screening. BMC Public Health. 2026;26(1):634. doi:10.1186/s12889-026-26310-x.Amadi CE, Ale OK, Okorafor UC, et al. Unmasking the contem­porary burden of hypertension in Lagos, Nigeria: insights from an opportunistic screening. BMC Public Health. 2026;26(1):634. doi:10.1186/s12889-026-26310-x.Beaney T, Kerr GK, Kiru G, et al. May Measurement Month 2022: results from the global blood pressure screening campaign. BMJ Glob Health. 2024;9(12):e016557. doi:10.1136/bmjgh-2024-016557.Beaney T, Kerr GK, Kiru G, et al. May Measurement Month 2022: results from the global blood pressure screening campaign. BMJ Glob Health. 2024;9(12):e016557. doi:10.1136/bmjgh-2024-016557.Tripathy JP, Thakur JS, Jeet G, et al. Alarmingly high prevalence of hypertension and pre-hypertension in North India-results from a large cross-­sectional STEPS survey. PloS One. 2017;12(12):e0188619. doi:10.1371/journal.pone.0188619.Tripathy JP, Thakur JS, Jeet G, et al. Alarmingly high prevalence of hypertension and pre-hypertension in North India-results from a large cross-­sectional STEPS survey. PloS One. 2017;12(12):e0188619. doi:10.1371/journal.pone.0188619.Peltzer K, Pengpid S. The prevalence and social determinants of hypertension among adults in Indonesia: A cross‐sectio­nal population‐based national survey. Int J Hypertens. 2018;1: 5610725. doi:10.1155/2018/5610725.Peltzer K, Pengpid S. The prevalence and social determinants of hypertension among adults in Indonesia: A cross‐sectio­nal population‐based national survey. Int J Hypertens. 2018;1: 5610725. doi:10.1155/2018/5610725.Mathur P, Kulothungan V, Leburu S, et al. National noncom­mu­nicable disease monitoring survey (NNMS) in India: Estima­ting risk factor prevalence in adult population. PloS One. 2021;16(3): e0246712. doi:10.1371/journal.pone.0246712.Mathur P, Kulothungan V, Leburu S, et al. National noncom­mu­nicable disease monitoring survey (NNMS) in India: Estima­ting risk factor prevalence in adult population. PloS One. 2021;16(3): e0246712. doi:10.1371/journal.pone.0246712.Calas L, Subiros M, Ruello M, et al. Hypertension prevalence, awareness, treatment and control in 2019 in the adult population of Mayotte. Eur J Public Health. 2022;32(3):408-14. doi:10.1093/eurpub/ckac015.Calas L, Subiros M, Ruello M, et al. Hypertension prevalence, awareness, treatment and control in 2019 in the adult population of Mayotte. Eur J Public Health. 2022;32(3):408-14. doi:10.1093/eurpub/ckac015.Abdul-­Razak S, Daher AM, Ramli AS, et al. Prevalence, aware­ness, treatment, control and socio demographic determinants of hypertension in Malaysian adults. BMC Public Health. 2016;16(1): 351. doi:10.1186/s12889-016-3008-y.Abdul-­Razak S, Daher AM, Ramli AS, et al. Prevalence, aware­ness, treatment, control and socio demographic determinants of hypertension in Malaysian adults. BMC Public Health. 2016;16(1): 351. doi:10.1186/s12889-016-3008-y.Rohla M, Haberfeld H, Sinzinger H, et al. Systematic screening for cardiovascular risk at pharmacies. Open Heart. 2016;3(2): e000497. doi:10.1136/openhrt-2016-000497.Rohla M, Haberfeld H, Sinzinger H, et al. Systematic screening for cardiovascular risk at pharmacies. Open Heart. 2016;3(2): e000497. doi:10.1136/openhrt-2016-000497.Pantell MS, Prather AA, Downing JM, et al. Association of social and behavioral risk factors with earlier onset of adult hypertension and diabetes. JAMA Netw Open. 2019;2(5):e193933. doi:10.1001/jamanetworkopen.2019.3933.Pantell MS, Prather AA, Downing JM, et al. Association of social and behavioral risk factors with earlier onset of adult hypertension and diabetes. JAMA Netw Open. 2019;2(5):e193933. doi:10.1001/jamanetworkopen.2019.3933.Lopez-­Neyman SM, Davis K, Zohoori N, et al. Racial disparities and prevalence of cardiovascular disease risk factors, cardio­metabolic risk factors, and cardiovascular health metrics among US adults: NHANES 2011-2018. Sci Rep. 2022;12(1):19475. doi:10.1038/s41598-022-21878-x.Lopez-­Neyman SM, Davis K, Zohoori N, et al. Racial disparities and prevalence of cardiovascular disease risk factors, cardio­metabolic risk factors, and cardiovascular health metrics among US adults: NHANES 2011-2018. Sci Rep. 2022;12(1):19475. doi:10.1038/s41598-022-21878-x.Mohamed SF, Mutua MK, Wamai R, et al. Prevalence, awareness, treatment and control of hypertension and their determinants: results from a national survey in Kenya. BMC Public Health. 2018;18(3):1219. doi:10.1186/s12889-018-6052-y.Mohamed SF, Mutua MK, Wamai R, et al. Prevalence, awareness, treatment and control of hypertension and their determinants: results from a national survey in Kenya. BMC Public Health. 2018;18(3):1219. doi:10.1186/s12889-018-6052-y.Du M, Yin S, Wang P, et al. Self-reported hypertension in Northern China: a cross-­sectional study of a risk prediction model and age trends. BMC Health Serv Res. 2018;18(1):475. doi:10.1186/s12913-018-3279-3.Du M, Yin S, Wang P, et al. Self-reported hypertension in Northern China: a cross-­sectional study of a risk prediction model and age trends. BMC Health Serv Res. 2018;18(1):475. doi:10.1186/s12913-018-3279-3.Li Z, Cao L, Zhou Z, et al. Factors influencing the progression from prehypertension to hypertension among Chinese middle-aged and older adults: a 2-year longitudinal study. BMC Public Health. 2023;23(1):339. doi:10.1186/s12889-022-14410-3.Li Z, Cao L, Zhou Z, et al. Factors influencing the progression from prehypertension to hypertension among Chinese middle-aged and older adults: a 2-year longitudinal study. BMC Public Health. 2023;23(1):339. doi:10.1186/s12889-022-14410-3.Montagna S, Pengo MF, Ferretti S, et al. Machine learning in hypertension detection: A study on world hypertension day data. J Med Syst. 2022;47(1):1. doi:10.1007/s10916-022-01900-5.Montagna S, Pengo MF, Ferretti S, et al. Machine learning in hypertension detection: A study on world hypertension day data. J Med Syst. 2022;47(1):1. doi:10.1007/s10916-022-01900-5.Huang W, Ying TW, Chin, WLC, et al. Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction. Sci Rep. 2022;12(1):1033. doi:10.1038/s41598-021-04649-y.Huang W, Ying TW, Chin, WLC, et al. Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction. Sci Rep. 2022;12(1):1033. doi:10.1038/s41598-021-04649-y.Adeneyi OA. Prevalence, Awareness and Correlates of Hyper­ten­sion Among Urban Public Workers in Ondo State, Nigeria. Online J Health Allied Sci. 2017;16(3):1.Adeneyi OA. Prevalence, Awareness and Correlates of Hyper­ten­sion Among Urban Public Workers in Ondo State, Nigeria. Online J Health Allied Sci. 2017;16(3):1.Agbaza-­Mogbojuri B. Lifestyle, stress, and treatment adherence as predictors of hypertension risk: A longitudinal public health study. WJBPHS. 2023;16(1):273-281. doi:10.30574/wjbphs.2023.16.1.0444.Agbaza-­Mogbojuri B. Lifestyle, stress, and treatment adherence as predictors of hypertension risk: A longitudinal public health study. WJBPHS. 2023;16(1):273-281. doi:10.30574/wjbphs.2023.16.1.0444.Ротарь О. П., Ильянова И. Н., Бояринова М. А. и др. Результаты Всероссий­ского скрининга артериальной гипертензии 2023. Российский кардио­ло­ги­ческий журнал. 2024;29(5):5931. doi:10.15829/1560-4071-2024-5931.Rotar OP, Ilyanova IN, Boyarinova MA, et al. 2023 All-­Rus­sian screening for hypertension: results. Russian Journal of Cardio­logy. 2024;29(5):5931. (In Russ) doi:10.15829/1560-4071-2024-5931.Islam SMS, Talukder A, Awal MA, et al. Machine learning approaches for predicting hypertension and its associated factors using population-­level data from three South Asian count­ries. Front Cardiovasc Med. 2022;9:839379. doi:10.3389/fcvm.2022.839379.Islam SMS, Talukder A, Awal MA, et al. Machine learning approaches for predicting hypertension and its associated factors using population-­level data from three South Asian count­ries. Front Cardiovasc Med. 2022;9:839379. doi:10.3389/fcvm.2022.839379.Sathish T, Kannan S, Sarma PS, et al. A risk score to predict hypertension in primary care settings in rural India. Asia-­Pac J Public Health. 2016;28(1 Suppl):26S-31S. doi:10.1177/1010539515604701.Sathish T, Kannan S, Sarma PS, et al. A risk score to predict hypertension in primary care settings in rural India. Asia-­Pac J Public Health. 2016;28(1 Suppl):26S-31S. doi:10.1177/1010539515604701.Абраров Р. А. Прогнозирование риска развития артериальной гипертензии у девушек-­подростков, родившихся недоношенными. Казанский медицинский журнал. 2018;99(4):580-5. doi:10.17816/KMJ2018-580.Abrarov RA. Prediction of risk of arterial hypertension among female adolescents born preterm. Kazan Medical Journal. 2018; 99(4):580-5. (In Russ.) doi:10.17816/KMJ2018-580.Mahmoud I, Sulaiman N, Hussein A, et al. A hypertension risk score for adults: a population-­based cross-­sectional study from the Dubai Household Survey 2019. Epidemiol Health. 2021;43: e2021064. doi:10.4178/epih.e2021064.Mahmoud I, Sulaiman N, Hussein A, et al. A hypertension risk score for adults: a population-­based cross-­sectional study from the Dubai Household Survey 2019. Epidemiol Health. 2021;43: e2021064. doi:10.4178/epih.e2021064.Kanellakis S, Mavrogianni C, Karatzi K, et al. Development and va­lidation of two self-reported tools for insulin resistance and hy­per­tension risk assessment in a European cohort: the Feel4Diabetes-­study. Nutrients. 2020;12(4):960. doi:10.3390/nu12040960.Kanellakis S, Mavrogianni C, Karatzi K, et al. Development and va­lidation of two self-reported tools for insulin resistance and hy­per­tension risk assessment in a European cohort: the Feel4Diabetes-­study. Nutrients. 2020;12(4):960. doi:10.3390/nu12040960.Oishi E, Hata J, Honda T, et al. Development of a risk prediction model for incident hypertension in Japanese individuals: the Hisayama Study. Hypertens Res. 2021;44(9):1221-9. doi:10.1038/s41440-021-00673-7.Oishi E, Hata J, Honda T, et al. Development of a risk prediction model for incident hypertension in Japanese individuals: the Hisayama Study. Hypertens Res. 2021;44(9):1221-9. doi:10.1038/s41440-021-00673-7.Chowdhury MZI, Leung AA, Sikdar KC, et al. Development and validation of a hypertension risk prediction model and construction of a risk score in a Canadian population. Sci Rep. 2022;12(1):12780. doi:10.1038/s41598-022-16904-x.Chowdhury MZI, Leung AA, Sikdar KC, et al. Development and validation of a hypertension risk prediction model and construction of a risk score in a Canadian population. Sci Rep. 2022;12(1):12780. doi:10.1038/s41598-022-16904-x.Kawasoe M, Kawasoe S, Kubozono T, et al. Development of a risk prediction score for hypertension incidence using Japanese health checkup data. Hypertens Res. 2022;45(4):730-40. doi:10.1038/s41440-021-00831-x.Kawasoe M, Kawasoe S, Kubozono T, et al. Development of a risk prediction score for hypertension incidence using Japanese health checkup data. Hypertens Res. 2022;45(4):730-40. doi:10.1038/s41440-021-00831-x.Zhao H, Zhang X, Xu Y, et al. Predicting the risk of hypertension based on several easy-to-collect risk factors: a machine learning method. Front Public Health. 2021;9:619429. doi:10.3389/fpubh.2021.619429.Zhao H, Zhang X, Xu Y, et al. Predicting the risk of hypertension based on several easy-to-collect risk factors: a machine learning method. Front Public Health. 2021;9:619429. doi:10.3389/fpubh.2021.619429.Kurniawan R, Utomo B, Siregar KN, et al. Hypertension prediction using machine learning algorithm among Indonesian adults. IAES Int J Artif Intell. 2023;12(2):776. doi:10.11591/ijai.v12.i2.pp776-784.Kurniawan R, Utomo B, Siregar KN, et al. Hypertension prediction using machine learning algorithm among Indonesian adults. IAES Int J Artif Intell. 2023;12(2):776. doi:10.11591/ijai.v12.i2.pp776-784.Ji W, Zhang Y, Cheng Y, et al. Development and validation of prediction models for hypertension risks: A cross-­sectional study based on 4,287,407 participants. Front Cardiovasc Med. 2022;9:928948. doi:10.3389/fcvm.2022.928948.Ji W, Zhang Y, Cheng Y, et al. Development and validation of prediction models for hypertension risks: A cross-­sectional study based on 4,287,407 participants. Front Cardiovasc Med. 2022;9:928948. doi:10.3389/fcvm.2022.928948.Nguyen TPL, Wright EP, Nguyen TT, et al. Cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in Vietnam. PloS One. 2016;11(5):e0155699. doi:10.1371/journal.pone.0155699.Nguyen TPL, Wright EP, Nguyen TT, et al. Cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in Vietnam. PloS One. 2016;11(5):e0155699. doi:10.1371/journal.pone.0155699.Kaur G, Chauhan AS, Prinja S, et al. Cost-effectiveness of population-­based screening for diabetes and hypertension in India: an economic modelling study. Lancet Public Health. 2022;7(1):e65-73. doi:10.1016/S2468-2667(21)00199-7.Kaur G, Chauhan AS, Prinja S, et al. Cost-effectiveness of population-­based screening for diabetes and hypertension in India: an economic modelling study. Lancet Public Health. 2022;7(1):e65-73. doi:10.1016/S2468-2667(21)00199-7.Neupane D, McLachlan CS, Mishra SR, et al. Effectiveness of a lifestyle intervention led by female community health volunteers versus usual care in blood pressure reduction (COBIN): an open-label, cluster-­randomised trial. Lancet Glob Health. 2018;6(1):e66-73. doi:10.1016/S2214-109X(17)30411-4.Neupane D, McLachlan CS, Mishra SR, et al. Effectiveness of a lifestyle intervention led by female community health volunteers versus usual care in blood pressure reduction (COBIN): an open-label, cluster-­randomised trial. Lancet Glob Health. 2018;6(1):e66-73. doi:10.1016/S2214-109X(17)30411-4.

The authors declare that there are no conflicts of interest present.